Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.56 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.56 |
| ▸ | EGFR | P00533 | 4/20 | 0.56 |
| ▸ | KIT | P10721 | 3/20 | 0.56 |
| ▸ | NEK2 | P51955 | 3/20 | 0.56 |
| ▸ | MELK | Q14680 | 2/20 | 0.56 |
| ▸ | PRKAA1 | Q13131 | 13/20 | 0.53 |
| ▸ | PRKAA2 | P54646 | 12/20 | 0.53 |
| ▸ | FLT3 | P36888 | 5/20 | 0.53 |
| ▸ | PLK4 | O00444 | 3/20 | 0.53 |
| ▸ | DCLK1 | O15075 | 3/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.53 |
| ▸ | RPS6KA5 | O75582 | 3/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.53 |
| ▸ | INSR | P06213 | 3/20 | 0.53 |
| ▸ | LCK | P06239 | 3/20 | 0.53 |
| ▸ | CSF1R | P07333 | 3/20 | 0.53 |
| ▸ | RET | P07949 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL143534 | 0.89 | KDR (0.72) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL5406592 | 0.87 | KDR (0.63) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL5410105 | 0.86 | MET (0.61) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL143097 | 0.86 | KDR (0.66) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL143419 | 0.86 | PDGFRB (0.54) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL5396558 | 0.86 | KDR (0.57) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL5417668 | 0.86 | SRC (0.59) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL3802797 | 0.86 | KDR (0.53) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL3802793 | 0.86 | KDR (0.53) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL144892 | 0.85 | KDR (0.61) | KDRPDGFRBFGFR1EGFRKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6599902-B2 | For treating or preventing a protein kinase related disorder | SUGEN, INC. | 2003-07-29 | — | — | US | claimed |
| US-20030125370-A1 | 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. | 2003-07-03 | — | — | US | claimed |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2005-12-22 | — | — | US | disclosed |
| US-6599902-B2 | For treating or preventing a protein kinase related disorder | SUGEN, INC. | 2003-07-29 | — | — | US | disclosed |
| US-20030125370-A1 | 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. | 2003-07-03 | — | — | US | disclosed |
| WO-2002096361-A2 | 5-ARALKYLSULFONYL-3- (PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | FGF1, FABP4, FGF2 | KDR 1077/4885PDGFRB 467/4885FGFR1 5/4885 |
| US-20030125370-A1 | 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | DMPK, ADK, MAP3K20 | KDR 398/4885PDGFRB 348/4885FGFR1 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.